KURA Kura Oncology Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Kura Oncology Inc reported revenue of $20.9M (up 36.5% from a year earlier), net income of −$68.3M and diluted EPS of −$0.77; over the last four quarters revenue was $77.2M and net income −$297M; for the fiscal year ended December 2025 revenue was $67.5M, up 25.2% on the year before.
KURA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $67.5M, gross profit n/a, operating income −$304M, net income −$279M (margin -412.9%), EPS −$3.18
- Fiscal year ended Dec 2024: revenue $53.9M, gross profit n/a, operating income −$193M, net income −$174M (margin -322.9%), EPS −$2.02
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$166M, net income −$153M (margin n/a), EPS −$2.08
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$140M, net income −$136M (margin n/a), EPS −$2.03
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$130M (margin n/a), EPS −$1.97
KURA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $20.9M (up 36.5% year over year), net income −$68.3M, EPS −$0.77
- Quarter ended Mar 31, 2026: revenue $18.3M (up 29.5% year over year), net income −$73.3M, EPS −$0.83
- Quarter ended Dec 31, 2025 (from the annual report): revenue $17.3M, net income −$81.0M, EPS −$0.92
- Quarter ended Sep 30, 2025: revenue $20.8M, net income −$74.1M, EPS −$0.85
- Quarter ended Jun 30, 2025: revenue $15.3M, net income −$66.1M, EPS −$0.75
- Quarter ended Mar 31, 2025: revenue $14.1M, net income −$57.4M, EPS −$0.66
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$19.2M, EPS −$0.21
- Quarter ended Sep 30, 2024: revenue n/a, net income −$54.4M, EPS −$0.63
- Quarter ended Jun 30, 2024: revenue n/a, net income −$50.8M, EPS −$0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$49.5M, EPS −$0.59
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$42.8M, EPS −$0.55
- Quarter ended Sep 30, 2023: revenue n/a, net income −$38.6M, EPS −$0.50
- Quarter ended Jun 30, 2023: revenue n/a, net income −$37.2M, EPS −$0.53
- Quarter ended Mar 31, 2023: revenue n/a, net income −$34.1M, EPS −$0.50
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$33.1M, EPS −$0.49
- Quarter ended Sep 30, 2022: revenue n/a, net income −$35.5M, EPS −$0.53
- Quarter ended Jun 30, 2022: revenue n/a, net income −$34.8M, EPS −$0.52
- Quarter ended Mar 31, 2022: revenue n/a, net income −$32.5M, EPS −$0.49
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$32.7M, EPS −$0.50
- Quarter ended Sep 30, 2021: revenue n/a, net income −$33.4M, EPS −$0.50
KURA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$64.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $134M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$125M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$110M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$105M, share buybacks n/a
KURA balance sheet
- Jun 30, 2026: cash $70.2M, total assets $588M, total liabilities $539M, shareholders' equity $48.4M, long-term debt $5.57M
- Mar 31, 2026: cash $39.1M, total assets $653M, total liabilities $545M, shareholders' equity $108M, long-term debt $9.75M
- Dec 31, 2025: cash $149M, total assets $738M, total liabilities $564M, shareholders' equity $174M, long-term debt $9.71M
- Sep 30, 2025: cash $95.3M, total assets $649M, total liabilities $407M, shareholders' equity $243M, long-term debt $5.34M
- Jun 30, 2025: cash $81.9M, total assets $682M, total liabilities $377M, shareholders' equity $305M, long-term debt $6.51M
- Mar 31, 2025: cash $51.3M, total assets $744M, total liabilities $379M, shareholders' equity $364M, long-term debt $7.65M
- Dec 31, 2024: cash $224M, total assets $760M, total liabilities $347M, shareholders' equity $414M, long-term debt $6.92M
- Sep 30, 2024: cash $49.5M, total assets $479M, total liabilities $55.1M, shareholders' equity $424M, long-term debt $7.76M
What is KURA's revenue?
Kura Oncology Inc reported $77.2M of revenue over its last four quarters, through June 30, 2026.
Is KURA profitable?
No. Kura Oncology Inc lost $297M over the last four quarters.
What is KURA's EPS?
Diluted earnings per share over the last four quarters were −$3.37; −$0.77 in the latest quarter.